ArticlePharmaceutical research2019
Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 65 citations in OpenAlex.
- Breast cancer: taxonomy, distribution analysis, risk factors, predictive biomarkers, and modern treatment method.Apoptosis : an international journal on programmed cell death · 2026Review
- Self-Immolative Domino Dendrimers as Anticancer-Drug Delivery Systems: A Review.Pharmaceutics · 2024Review
- Polymer-Based Drug Delivery Systems for Cancer Therapeutics.Polymers · 2024Review
- Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies.Journal of clinical medicine · 2023Review
- Investigation of the Therapeutic Effects of Palbociclib Conjugated Magnetic Nanoparticles on Different Types of Breast Cancer Cell Lines.Cellular and molecular bioengineering · 2023Article
- Review
- Dendrimers as Modifiers of Inorganic Nanoparticles for Therapeutic Delivery in Cancer.Pharmaceutics · 2023Review
- Nanoparticles Loaded with Docetaxel and Resveratrol as an Advanced Tool for Cancer Therapy.Biomedicines · 2022Review
- Application of Dendrimers in Anticancer Diagnostics and Therapy.Molecules (Basel, Switzerland) · 2022Review
- Nanotheranostics for Image-Guided Cancer Treatment.Pharmaceutics · 2022Review
- Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With EnhancedFrontiers in pharmacology · 2022Article
- An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010-2020 review.Nanoscale advances · 2021Review
- A Review on Drug Delivery System for Tumor Therapy.Frontiers in pharmacology · 2021Review
- Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways.Computational and structural biotechnology journal · 2021Article
- The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment.Pharmaceutics · 2020Review
- Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer.Cancers · 2020Review
- A Group of Complexes Based on PAMAM and Quantum Dots Used in Clinical Immunoassays.Nanoscale research letters · 2020Article
- Mannose receptor 1 expression does not determine the uptake of high-density mannose dendrimers by activated macrophages populations.PloS one · 2020Article
- Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy.International journal of nanomedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeConjugation of nanocarriers with antibodies that bind to specific membrane receptors that are overexpressed in cancer cells enables targeted delivery. In the present study, we developed and synthesised two PAMAM dendrimer-trastuzumab conjugates that carried docetaxel or paclitaxel, specifically targeted to cells which overexpressed HER-2.
methodsThe
resultsThe PAMAM-drug-trastuzumab conjugates in particular showed extremely high toxicity toward the HER-2-positive SKBR-3 cells and very low toxicity towards to HER-2-negative MCF-7 cells. As expected, the HER-2-positive SKBR-3 cell line accumulated trastuzumab from both conjugates rapidly; but surprisingly, although a large amount of PAMAM-ptx-trastuzumab conjugate was observed in the HER-2-negative MCF-7 cells. Confocal microscopy confirmed the intracellular localisation of analysed compounds. The key result of fluorescent imaging was the identification of strong selective binding of the PAMAM-doc-trastuzumab conjugate with HER-2-positive SKBR-3 cells only.
conclusionsOur results confirm the high selectivity of PAMAM-doc-trastuzumab and PAMAM-ptx-trastuzumab conjugates for HER-2-positive cells, and demonstrate the utility of trastuzumab as a targeting agent. Therefore, the analysed conjugates present an promising approach for the improvement of efficacy of targeted delivery of anticancer drugs such as docetaxel or paclitaxel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.